-

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Lumen Technologies, Inc. (LUMN) f/k/a CenturyLink Inc.

SAN DIEGO--(BUSINESS WIRE)--The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lumen Technologies, Inc. (NYSE: LUMN) securities between September 14, 2020 and February 7, 2023, for violations of the Securities Exchange Act of 1934. Lumen, formerly CenturyLink Inc. (NYSE: CTL), is a communications company.

What Now: Similarly situated shareholders may be eligible to participate in the class action against Lumen. Shareholders who want to act as lead plaintiff for the class must file their papers by May 2, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case About: Lumen Technologies, Inc. (LUMN) Misled Investors Regarding its Expansion into SMB and Residential Markets

According to the complaint, during the class period, defendants represented that Lumen was, among other things, “investing heavily in our consumer fiber business” and “aggressively taking market share in our small business segment.” Defendants also represented that “we continue expanding our Quantum Fiber footprint and increasing our penetration” and “we're not capital-constrained. So as we continue to improve our penetration and performance, we'll continue to expand our footprint, and we believe we've got a long runway for growth in -- within Lumen in Quantum Fiber.”

However, Lumen was experiencing serious headwinds that were impeding its ability to grow its newly-targeted fiber markets. Defendants failed to disclose that: (i) various headwinds were impeding the Company’s ability to invest in and grow its Quantum Fiber brand; (ii) Quantum Fiber was not progressing as was represented to the investing public; (iii) Lumen’s management was reassessing its strategic priorities and had placed a hold on the plans to quickly scale up the Quantum Fiber brand; and (iv) as a result of Lumen’s decision to delay expansion of Quantum Fiber, the Company’s results and metrics were negatively impacted and the scaling up of Quantum Fiber would not occur until, at the earliest, the end of 2023.

Beginning on February 9, 2022, defendants began to admit that Lumen's expansion into small and medium business ("SMB") and residential fiber services was occurring slower than previously represented. On this news, Lumen’s stock price declined $1.99, from a close of $12.82 per share on February 9, 2022, to a close of $10.83 on February 10, 2022.

On November 2, 2022, Lumen’s Chief Executive Officer admitted, “let me be clear, we are not yet at the pace of build we expect or want” with respect to the Company’s development of its Quantum Fiber brand. On this news, Lumen’s stock price declined $1.25, from a close of $7.05 per share on November 2, 2022, to a close of $5.80 on November 3, 2022.

Finally, on February 7, 2023, defendants admitted they had pressed “more of a stop button than a pause button” on Lumen’s investment into the Quantum Fiber network and expansion into the SMB and residential markets while the Company re-evaluated its strategic priorities. On this news, Lumen’s stock price declined $1.04, from a close of $4.99 per share on February 7, 2023, to a close of $3.95 on February 8, 2023.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Lumen Technologies, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:LUMN

Release Summary
Lumen Technologies, Inc. (LUMN) Misled Investors Regarding its Expansion into SMB and Residential Markets
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom